Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses
Background Bintrafusp alfa (BA) is a bifunctional fusion protein designed for colocalized, simultaneous inhibition of two immunosuppressive pathways, transforming growth factor-β (TGF-β) and programmed death-ligand 1 (PD-L1), within the tumor microenvironment (TME). We hypothesized that targeting PD...
Main Authors: | Feng Jiang, Hong Wang, Yan Lan, Guozhong Qin, Jin Qi, Bo Marelli, Huakui Yu, Kin-Ming Lo, Dong Zhang, Hui Huang, Hong Ma, Tsz-Lun Yeung, Ansgar A Wegener, Somdutta Saha, Mira Toister-Achituv, Molly H Jenkins, Li-Ya Chiu, Adam Lazorchak, Ohad Tarcic, George Locke, Doron Kalimi, Alec W Gross, Melissa G Derner, Maria Soloviev, Mathieu Botte, Aroop Sircar, Vanita D Sood |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/10/7/e004122.full |
Similar Items
-
NHS-IL12 and bintrafusp alfa combination therapy enhances antitumor activity in preclinical cancer models
by: Chunxiao Xu, et al.
Published: (2022-02-01) -
609 Combining bintrafusp alfa with abituzumab enhances suppression of the TGF-β signaling pathway
by: Feng Jiang, et al.
Published: (2021-11-01) -
Risk assessment of drug–drug interaction potential for bintrafusp alfa with cytochrome P4503A4 substrates: A totality of evidence approach
by: Yulia Vugmeyster, et al.
Published: (2022-12-01) -
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
by: Renee N Donahue, et al.
Published: (2022-04-01) -
6 Immune correlates of clinical benefit in patients with HPV-associated malignancies treated with bintrafusp alfa
by: Jeffrey Schlom, et al.
Published: (2021-11-01)